Survey to characterize resistance training habits in GLP-1RA users for muscle preservation

Type 2 diabetes and obesity are major public health challenges, with glucagon-like peptide-1 receptor agonists (GLP-1RAs) like semaglutide and liraglutide becoming increasingly common treatments. While highly effective for weight loss, a significant concern is the concomitant loss of lean muscle mass, which can impair physical function and quality of life. Resistance training is the most effective strategy to preserve and build muscle, yet most adults do not meet recommended guidelines. Understanding the resistance training behaviors of GLP-1RA users is crucial to develop targeted interventions that mitigate muscle loss and maintain functional strength.

This research will systematically collect information from adults 18 years or older currently taking a GLP-1 receptor agonist (semaglutide, liraglutide, tirzepatide, etc.) for type 2 diabetes, overweight, or obesity. Participants must have been on the medication for at least three months at a stable dose. The primary objective is to understand their resistance training habits, including frequency, duration, intensity, and muscle groups targeted. The study will also assess perceived strength, ability to perform daily activities, and factors that facilitate or hinder resistance training while on GLP-1RAs.